’  ’ ”   Mallinckrodt Pharmaceuticals’ agreed to pay    charges it used its monopoly on a lupus   and  drug, Acthar, to   unfairly jack up its price.    The FTC has been looking into the matter since 2014, and   the  that it was  ” ’  ’ ’  ’ ’  ’ ’  ’ ” Here’s the full statement from the FTC: ”